SEC Form 4 · accession 0000899243-17-002289
Larimar Therapeutics, Inc. · LRMR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas E. Hughes
Officer — President and CEO · Director
Period of report
Jan 27, 2017
Accepted (ET)
Jan 31, 2017 · 5:32 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001374690
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $4.05 | Jan 27, 2017 | A | 319,000 | A | — | Jan 27, 2027 | Common Stock | 319,000 | 319,000 | D |
Explanation of responses
- F125% of this option vests on January 27, 2018, and the remainder vests in equal monthly installments thereafter over 36 months.